LOXL3 and cutaneous melanoma: The differential expression analyses perfomed using GEPIA2 revealed a significantly higher mRNA expression level for LOXL3 and NES in cutaneous melanomas, both with and without confirmed BRAF mutations, compared to normal skin samples.